Myeloproliferative Neoplasms | Specialty

Risk Factors and Prognosis of Polycythemia Vera

May 31st 2017

Heterogeneity of Polycythemia Vera

May 31st 2017

Changes Planned for MPN Guidelines

May 26th 2017

The National Comprehensive Cancer Network published its first set of guidelines for myeloproliferative neoplasms in October 2016 and is already looking to update and expand these guidelines.

Clinical Trial Enrollment Needed to Advance MPN Field

May 19th 2017

Kebede H. Begna, MD, discusses the diagnosis and treatment of patients with myeloproliferative neoplasms, including polycythemia vera, essential thrombocytopenia, and myelofibrosis.

Dr. Begna on Recent Advancements in MPNs

May 16th 2017

Kebede H. Begna, MD, assistant professor of Medicine, Mayo Clinic, discusses some of the recent advancements in the field of myeloproliferative neoplasms (MPNs).

Dr. Mauro on Current and Emerging Agents for MPNs

February 25th 2017

Michael J. Mauro, MD, a hematologist and leader of the Myeloproliferative Neoplasms Program at Memorial Sloan Kettering Cancer Center, discusses some of the emerging and current therapies for patients with myeloproliferative neoplasms (MPNs).

Dr. Mesa on Incorporating MPN Guidelines into Clinical Practice

February 25th 2017

Ruben A. Mesa, MD, chair of Hematology, Mayo Clinic, discusses how community oncologists can incorporate the NCCN Guideline for Myeloproliferative Neoplasms (MPNs) into clinical practice.

Dr. Mascarenhas Discusses Pacritinib in Myelofibrosis

February 20th 2017

John Mascarenhas, MD, associate professor of Medicine, Mount Sinai School of Medicine, discusses pacritinib in patients with myelofibrosis.

Landscape for Myeloproliferative Disorders Becoming More Defined With Improved Treatments, Biomarkers

January 11th 2017

Emerging therapies in myeloproliferative disorders such as chronic myeloid leukemia, polycythemia vera, and myelofibrosis could have the potential to shake up the landscape.

FDA Lifts Clinical Hold on Pacritinib

January 5th 2017

The FDA has lifted its clinical hold on trials exploring pacritinib, according to CTI BioPharma, the developer of the JAK2/FLT3 inhibitor.

Dr. Patnaik on Activity of SL-401 in Chronic Myelomonocytic Leukemia

December 31st 2016

Mrinal Patnaik, MBBS, hematologist, Mayo Clinic, discusses the encouraging results seen in a phase II trial evaluating the activity of SL-401 in patients with advanced, high risk myeloproliferative neoplasms, including chronic myelomonocytic leukemia.

Dr. Mascarenhas on the MPD-RC 112 Study in PV and ET

December 30th 2016

John Mascarenhas, MD, associate professor of Medicine, Mount Sinai School of Medicine, discusses the results from the interim analysis of the MPD-RC 112 study, which compared frontline pegylated interferon-alpha-2a with hydroxyurea in the treatment of patients with high risk polycythemia vera and essential thrombocythemia.

High Rates of Symptoms, Impairment, With Myeloproliferative Neoplasms

December 20th 2016

Patients with myeloproliferative disorders have a high symptom burden that significantly affects emotional status, quality of life, and functional ability.

Ruxolitinib Demonstrates Consistent Survival Benefit in Myelofibrosis

December 19th 2016

Patients with intermediate/high-risk myelofibrosis had improved survival when treated long term with the Janus kinase inhibitor ruxolitinib.

Novel Agent Slows High-Risk Myelofibrosis in Initial Trial

December 19th 2016

A third of patients with previously treated, high- and intermediate-risk myelofibrosis had objective responses to the investigational Second mitochondria-derived activator of caspases mimetic LCL161.

Expanded Access Data Confirm Safety, Efficacy of Ruxolitinib in Myelofibrosis

December 16th 2016

Worldwide clinical experience with the JAK1/2 inhibitor ruxolitinib (Jakafi) in patients with myelofibrosis has yielded safety and efficacy data similar to results of a pivotal randomized trial.

Emerging Treatments, New Guidelines Advance MPN Care

December 14th 2016

The NCCN recently published new guidelines for myeloproliferative neoplasms (MPNs), with an emphasis on diagnosis, treatment, and supportive care strategies for myelofibrosis. Subsequent editions will focus more on other MPNs, including essential thrombocythemia, polycythemia vera.

More Randomized Data Support Pacritinib Efficacy in Myelofibrosis

December 8th 2016

Patients with myelofibrosis and thrombocytopenia had significantly greater reductions in spleen volume and symptoms when treated with the multikinase inhibitor pacritinib, compared with the best available therapy.

Dr. Patnaik on a Study Examining SL-401 in Patients With Myeloproliferative Neoplasms

December 4th 2016

Mrinal S. Patnaik, MBBS, hematologist, Mayo Clinic, discusses a study investigating SL-401 in patients with myeloproliferative neoplasms during the American Society of Hematology (ASH) Annual Meeting.

Dr. Mesa on Upcoming Updates to NCCN Guideline for MPNs

December 3rd 2016

Ruben A. Mesa, MD, chair of Hematology, Mayo Clinic, discusses updates that are expected in 2017 to the NCCN Guideline for Myeloproliferative Neoplasms (MPNs).